Medical Data Vision Co., Ltd.

Informe acción TSE:3902

Capitalización de mercado: JP¥19.9b

Medical Data Vision Crecimiento futuro

Future controles de criterios 4/6

Medical Data Vision is forecast to grow earnings and revenue by 22.5% and 10.9% per annum respectively. EPS is expected to grow by 22.5% per annum. Return on equity is forecast to be 18.6% in 3 years.

Información clave

22.5%

Tasa de crecimiento de los beneficios

22.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare Services16.4%
Tasa de crecimiento de los ingresos10.9%
Rentabilidad financiera futura18.6%
Cobertura de analistas

Low

Última actualización29 Aug 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Medical Data Vision (TSE:3902) Will Pay A Dividend Of ¥6.50

Oct 03
Medical Data Vision (TSE:3902) Will Pay A Dividend Of ¥6.50

Medical Data Vision (TSE:3902) Has Affirmed Its Dividend Of ¥6.50

Sep 19
Medical Data Vision (TSE:3902) Has Affirmed Its Dividend Of ¥6.50

Medical Data Vision (TSE:3902) Has Affirmed Its Dividend Of ¥6.50

Aug 10
Medical Data Vision (TSE:3902) Has Affirmed Its Dividend Of ¥6.50

Medical Data Vision Co., Ltd. (TSE:3902) Stocks Shoot Up 25% But Its P/E Still Looks Reasonable

Jun 25
Medical Data Vision Co., Ltd. (TSE:3902) Stocks Shoot Up 25% But Its P/E Still Looks Reasonable

Why Medical Data Vision Co., Ltd. (TSE:3902) Could Be Worth Watching

Jun 13
Why Medical Data Vision Co., Ltd. (TSE:3902) Could Be Worth Watching

Previsiones de crecimiento de beneficios e ingresos

TSE:3902 - Estimaciones futuras de los analistas y datos financieros pasados (JPY Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/20268,7101,0079161,0413
12/31/20257,8607877317253
12/31/20247,0776205215673
6/30/20246,197448103250N/A
3/31/20246,248689N/AN/AN/A
12/31/20236,4199791,5861,616N/A
9/30/20236,264753N/AN/AN/A
6/30/20236,2507931,5171,577N/A
3/31/20236,152832N/AN/AN/A
12/31/20226,104870857910N/A
9/30/20226,0471,164N/AN/AN/A
6/30/20225,8931,125967989N/A
3/31/20225,7541,091N/AN/AN/A
12/31/20215,6721,0871,0581,082N/A
9/30/20215,378872N/AN/AN/A
6/30/20215,1688651,2231,253N/A
3/31/20214,966858N/AN/AN/A
12/31/20204,579700937964N/A
9/30/20204,422770N/AN/AN/A
6/30/20204,286700722738N/A
3/31/20204,199637N/AN/AN/A
12/31/20194,0265541,1211,202N/A
9/30/20193,931522N/AN/AN/A
6/30/20193,891329490607N/A
3/31/20193,743188N/AN/AN/A
12/31/20183,577692120N/A
9/30/20183,519137N/AN/AN/A
6/30/20183,36418260231N/A
3/31/20183,283257N/AN/AN/A
12/31/20173,225354N/A486N/A
9/30/20173,009178N/AN/AN/A
6/30/20172,929272N/A635N/A
12/31/20162,632178N/A196N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: 3902's forecast earnings growth (22.5% per year) is above the savings rate (0.3%).

Beneficios vs. Mercado: 3902's earnings (22.5% per year) are forecast to grow faster than the JP market (8.9% per year).

Beneficios de alto crecimiento: 3902's earnings are expected to grow significantly over the next 3 years.

Ingresos vs. Mercado: 3902's revenue (10.9% per year) is forecast to grow faster than the JP market (4.2% per year).

Ingresos de alto crecimiento: 3902's revenue (10.9% per year) is forecast to grow slower than 20% per year.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: 3902's Return on Equity is forecast to be low in 3 years time (18.6%).

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y